BioNano Genomics (BNGO) Stock Statistics & Valuation Metrics
Total Valuation
BioNano Genomics has a market cap or net worth of MXN 301.96M. The enterprise value is MXN 9.33M.
- Market Cap
- MXN 301.96M
- Enterprise Value
- MXN 9.33M
Share Statistics
BioNano Genomics has 13,976,957 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 13,976,957
- Owned by Insiders
- 0.96%
- Owned by Institutions
- 2.09%
Financial Efficiency
BioNano Genomics’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -64.63%.
- Return on Equity (ROE)
- -0.59
- Return on Assets (ROA)
- -0.36
- Return on Invested Capital (ROIC)
- -64.63%
- Return on Capital Employed (ROCE)
- -0.66
- Revenue Per Employee
- 296.96K
- Profits Per Employee
- -274.95K
- Employee Count
- 96
- Asset Turnover
- 0.39
- Inventory Turnover
- 4.08
Valuation Ratios
The current PE Ratio of BioNano Genomics is -0.31. BioNano Genomics’s PEG ratio is -0.00.
- PE Ratio
- -0.31
- PS Ratio
- 0.45
- PB Ratio
- 0.42
- Price to FCF
- -0.66
- Price to Operating Cash Flow
- -0.65
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, BioNano Genomics had revenue of 28.51M and earned -26.39M in profits. Earnings per share was -4.85.
- Revenue
- 28.51M
- Gross Profit
- 6.26M
- Operating Income
- -33.34M
- Pretax Income
- -26.33M
- Net Income
- -26.39M
- EBITDA
- -16.30M
- Earnings Per Share (EPS)
- -4.85
Cash Flow
In the last 12 months, operating cash flow was -20.48M and capital expenditures 0, giving a free cash flow of -20.48M billion.
- Operating Cash Flow
- -20.48M
- Free Cash Flow
- -20.48M
- Free Cash Flow per Share
- -1.77
Dividends & Yields
BioNano Genomics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -151.22%
- Earnings Yield
- -242.22%
Stock Price Statistics
- Beta
- -0.33
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 69.35
- 200-Day Moving Average
- 69.35
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
BioNano Genomics upcoming earnings date is Nov 10, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 10, 2026
- Next Earnings Date
- Nov 10, 2026
- Ex-Dividend Date
- ―
Financial Position
BioNano Genomics as a current ratio of 1.98, with Debt / Equity ratio of 15.57%
- Current Ratio
- 1.98
- Quick Ratio
- 1.74
- Debt to Market Cap
- 0.72
- Net Debt to EBITDA
- -0.24
- Interest Coverage Ratio
- -111.88
Taxes
In the past 12 months, BioNano Genomics has paid 67.00K in taxes.
- Income Tax
- 67.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
BioNano Genomics EV to EBITDA ratio is -0.74, with an EV/FCF ratio of -0.81.
- EV to Sales
- 0.55
- EV to EBITDA
- -0.74
- EV to Free Cash Flow
- -0.81
- EV to Operating Cash Flow
- -0.81
Balance Sheet
BioNano Genomics has MXN 9.92M in cash and marketable securities with MXN 6.70M in debt, giving a net cash position of MXN 3.21M billion.
- Cash & Marketable Securities
- MXN 9.92M
- Total Debt
- MXN 6.70M
- Net Cash
- MXN 3.21M
- Net Cash Per Share
- MXN 0.23
- Tangible Book Value Per Share
- MXN 2.59
Margins
Gross margin is 47.50%, with operating margin of -106.67%, and net profit margin of -106.58%.
- Gross Margin
- 47.50%
- Operating Margin
- -106.67%
- Pretax Margin
- -106.36%
- Net Profit Margin
- -106.58%
- EBITDA Margin
- -74.27%
- EBIT Margin
- -105.66%
Analyst Forecast
The average price target for BioNano Genomics is MXN 75.53, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- MXN 75.53
- Price Target Upside
- 8.91% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―